Neuroblastoma (NB) is a frequently lethal tumor of childhood. MYCN amplification accounts for the aggressive phenotype in a subset while the majority have no consistently identified molecular aberration but frequently express MYC at high levels. We hypothesized that activated Wnt/b-catenin (CTNNB1) signaling might account for this as MYC is a b-catenin transcriptional target and multiple embryonal and neural crest malignancies have oncogenic alterations in this pathway. NB cell lines without MYCN amplification express higher levels of MYC and b-catenin (with aberrant nuclear localization) than MYCNamplified cell lines. Evidence for aberrant b-catenin-TCF transcriptional activity was demonstrated using expression profiles from 73 primary NBs. Findings included increased WNT ligands (WNT1, WNT6, WNT7A, WNT10B), DVL1 and TCF7 expression in high-risk NBs without MYCN amplification, consistent with canonical b-catenin signaling. More directly, Patterns of Gene Expression and Gene Set Enrichment Analyses demonstrated b-catenin target genes (for example, MYC, PPARD, NRCAM, CD44, TCF7) as coordinately upregulated in high-risk NBs without MYCN amplification in comparison to high-risk MYCN-amplified or intermediate-risk NBs, supporting pathway activation in this subset. Thus, high-risk NBs without MYCN amplification may deregulate MYC and other oncogenic genes via altered b-catenin signaling providing a potential candidate pathway for therapeutic inhibition.
Introduction
Neuroblastoma (NB) is a childhood embryonal malignancy arising in the peripheral sympathetic nervous system. Half of all children with NB present with features that define their tumors as high risk with poor overall survival despite intensive therapy (Matthay et al., 1999) . A subset of these tumors are characterized by high-level genomic amplification of the MYCN proto-oncogene (Matthay et al., 1999) but the remainder have no consistently identified aberration to account for their aggressive phenotype.
MycN is a member of the Myc family of genes (MYC, MYCN, MYCL) that play a central role in diverse cellular processes (Grandori et al., 2000) and their deregulated expression frequently contributes to neoplasia (Cole and McMahon, 1999) . NB-derived cell lines without MYCN amplification generally express MYC rather than MYCN, often at higher levels than normal tissues (Sadee et al., 1987) . MYC amplification (in contrast to MYCN) is rare in NB (Kohl et al., 1983) yet alternative mechanisms of MYC deregulation have not been elucidated.
A recurring paradigm in embryonal oncogenesis is the aberrant appropriation of developmental programs. Indeed, activation of the Notch, Sonic hedgehog and Wnt/b-catenin (CTNNB1) developmental programs contribute to malignant transformation (Taipale and Beachy, 2001; Allenspach et al., 2002; Giles et al., 2003) . Wnt/b-catenin signaling may be of particular relevance to NBs, which arise from migratory neural crest-derived neuroblasts, as this program mediates neural crest cell fate and neural stem-cell expansion (Chenn and Walsh, 2002; Zechner et al., 2003; Lee et al., 2004) . Further, Wnt/b-catenin signaling is aberrantly activated in multiple embryonal and neural crest-derived malignancies (Giles et al., 2003) .
Activation of the canonical Wnt/b-catenin pathway leads to transactivation of target genes, which may play a direct role in tumorigenesis (Goss and Groden, 2000; Moon et al., 2002) . During the nonactivated state, b-catenin is sequestered in the cytosol by a complex that includes APC, GSK3B, Axin proteins and others. This structure facilitates phosphorylation of b-catenin targeting it for proteasomal degradation (Goss and Groden, 2000) and b-catenin targets remain actively repressed. Canonical pathway activation hinders b-catenin phosphorylation resulting in enhanced protein stability and nuclear translocation, where it forms a heterodimeric transcription factor with proteins of the TCF/LEF family and transactivates target genes that include MYC (He et al., 1998) , CCND1 and others (Miller et al., 1999; Hecht and Kemler, 2000) .
Malignant cells may activate the canonical pathway through gain-of-function mutations in b-catenin, by inactivation of components of the scaffolding complex (Giles et al., 2003) , or by autocrine Wnt/receptor signaling (Bafico et al., 2004) . We hypothesized that deregulated b-catenin signaling may occur in high-risk NBs without MYCN amplification resulting in transactivation of MYC and other target genes to induce an aggressive phenotype.
Results
There is a reciprocal relationship between MYC and MYCN expression in NB-derived cell lines. Cell lines with MYCN gene amplification expressed high levels of MYCN and undetectable MYC (Figures 1a and b) . In contrast, NB cell lines without MYCN amplification expressed MYC in the absence of detectable MYCN with the exception of the NBL-S cell line. This unique nonamplified cell line has a prolonged MycN protein half-life (Cohn et al., 1990) . Of note, control HepG2 cells express high levels of MYC due to a hemizygous intragenic deletion that hinders b-catenin degradation and leads to canonical signaling (He et al., 1998) .
NB cell lines without MYCN amplification express b-catenin at high levels with aberrant nuclear localization. Subcellular protein fractions were assessed for expression of b-catenin (Figures 1c and d) . NALM-6 and PB1 controls demonstrate modest b-catenin expression limited to the cytosol. HepG2 cells express both wild-type and mutant b-catenin, with the stabilized truncated b-catenin in higher abundance and enriched in the nuclear fraction (positive control for deregulated b-catenin).
NB cells with MYCN amplification express b-catenin comparable to that of the wild-type protein in HepG2. The majority is cytosolic, with a minor nuclear contribution (o30% of total). In contrast, MYCN single-copy cell lines express higher levels of b-catenin overall as well as a higher amount in the nucleus (similar to that for the mutant allele in HepG2). The absence of significant nuclear b-tubulin argues against cytosolic spillover contributing to artifactual localization (see Supplementary Figure S1 ).
Immunofluorescence cytology confirmed aberrant nuclear localization (Figure 2a ). HepG2 cells demonstrated higher b-catenin expression with strong nuclear localization in B25% of cells (arrowhead). The MYCNamplified cell lines show b-catenin largely restricted to the cytosol (IMR5 shown). In contrast, SK-N-AS and LA-N-6 demonstrated higher b-catenin expression with moderate and marked homogeneous nuclear localization, respectively. In addition to validating localization, No activating b-catenin mutations are identified in NB cell lines or primary NBs. No aberrantly migrating b-catenin bands to suggest truncating deletions were present in NB (Figure 1c ). Single-strand conformational polymorphism (SSCP) was used to analyse the critical b-catenin regulatory region in NB cell lines (N ¼ 12) and primary NBs (N ¼ 26) and no aberrantly migrating bands were detected ( Table 1 ). The HepG2 cell line has a hemizygous mutant b-catenin allele with an exon 3 deletion. Since the SSCP primers amplify within exon 3, HepG2 is hemizygous for this PCR product and the banding pattern appears wild type. To exclude similar larger deletions in NB cells, we used primers within exons 2 and 4 to amplify a larger genomic fragment encompassing the entire regulatory domain. No internal deletions were identified in NB while HepG2 demonstrated the internal deletion (data not shown).
Despite aberrant nuclear b-catenin, NB-derived cell lines did not exhibit enhanced b-catenin-TCF transcriptional activity. The native b-catenin-TCF luciferase reporter, pTOPflash, was used to assess b-catenin-TCF transcriptional activity in NB and results were compared with those for the control reporter pFOPflash that has mutated b-catenin binding sites (Figure 2b) . None of the NB cell lines showed specific b-catenin transactivation. Still, evidence for relative b-catenin target gene upregulation (or at least derepression) was demonstrated using expression profiles and Q-PCR (see Supplementary  Figures S2 and S3) .
We next looked for evidence of b-catenin pathway activation in primary NBs. Expression profiles were obtained from primary NBs (Wang et al., 2006) including 21 from intermediate-risk tumors (IR Group) and 52 from high-risk tumors (32 without MYCN amplification (HR-NA) and 20 with MYCN amplification (HR-A)); see Table 2 and 'Materials and methods' section. We defined a b-catenin target gene set using the Wnt/b-catenin database (www.stanford.edu/Brnusse/wntwindow.html). Twenty-six genes were identified and we sought to determine whether these alone could discriminate highrisk tumors with and without MYCN amplification (Figure 3a ). This unsupervised method segregated HR tumors into groups with 25 of 26 (96%) HR-NA NBs and 19 of 26 (73%) HR-A NBs, and supports the hypothesis that these genes alone are discriminatory, with coordinate b-catenin pathway activation in HR-NA tumors. Five of seven tumors from children less than 18 months of age segregated with the HR-A tumors with reduced target gene expression. Thus, these findings do not represent age-related differences whereby expression of this developmental program in tumors from younger children is temporally but normally upregulated. Only six tumors met high-risk criteria in the absence of metastases (INSS stage 3) and half segregated within the high b-catenin target gene subset, half in the low expressers suggesting that canonical b-catenin signaling is not a surrogate metastasis signature.
These differences were not the result of the incidental inclusion of MYCN targets in the gene list as we repeated the analyses 10 times using permuted gene lists consisting of randomly generated 26 gene sets and none Oligonucleotide array results were previously validated for 18 genes using qRT-PCR with each having a Deregulated b-catenin in neuroblastoma X Liu et al microarray-to-qRT-PCR correlation o0.0001 (Wang et al., 2006) . We performed semiquantitative qRT-PCR for three additional b-catenin target genes from random tumors selected from HR-NA and HR-A NBs. qRT-PCR data was tightly correlated with oligonucleotide array expression data for these genes as well ( Figure 5 ). Distinct cellular processes often coregulate multiple genes and modest changes in a coordinated direction across such genes may be as biologically meaningful as single genes with dramatic fold changes, though less apparent. We used Gene Set Enrichment Analyses (GSEA) to confirm the b-catenin target alterations between tumor groups (Subramanian et al., 2005) . We confirmed enrichment of b-catenin target genes in HR-NA versus HR-A tumors, with an enrichment score (ES) of 0.45 (P ¼ 0.044) (Figure 6 ), with 17 genes contributing markedly to the ES (making up the 'leading edge' subset). These included CD44, NRCAM, MYC, MET, FST, TCF7, L1CAM, MYCBP, LEF1, PPARD, JUN, GAS, CCND1, FGF18, BIRC5, PLAUR and MMP7. Statistical significance was confirmed using an empirical phenotypebased permutation test (Subramanian et al., 2005) .
We next sought confirmation that HR-NA NBs had coordinate up-regulation of b-catenin targets in comparison to IR tumors. Despite an ES consistent with upregulation of the b-catenin targets in HR-NA NBs (0.33), the analysis did not meet statistical significance (P ¼ 0.37). Still, 9 of the 17 genes that comprised the 'leading edge subset' that account for the maximal enrichment signal (Subramanian et al., 2005) remained enriched in the HR-NA cohort. These included TCF7, MET, MYC, GAS, BIRC5, MYCBP, FGF18, FST and MMP7. No b-catenin target was enriched in the direction of higher expression in the IR group. These data support that there are a subset of core b-catenin target genes upregulated in high-risk NBs without MYCN amplification (HR-NA) in comparison to IR NBs.
We assessed expression of upstream signaling components to determine possible mechanisms of pathway activation. WNT1, WNT6, WNT7A and WNT10B were all more highly expressed in HR-NA NBs. Soluble factors that may regulate Wnt/receptor interactions are also abundant in NBs though no differential expression was apparent. Wnt receptors include the Frizzled (FZD) and LDLreceptor-related protein (LRP) families: FZD2 and LRP5 were both more abundantly expressed in HR-A NBs (Table 3) .
Wnt signaling activates disheveled homologs (DVL1, DVL3) and FRAT2 to initiate negative regulatory effects on AXIN and GSK3 and increase b-catenin activity. Other members of this scaffold complex include APC and BTRC. Most of these components (including b-catenin itself) are not differentially expressed (Table 3) , which is not surprising given that pathway components are primarily regulated post-translationally. However, DVL1 is upregulated in HR-NA tumors in a manner predicted to augment b-catenin activity.
Nuclear regulators of b-catenin signaling include members of the TCF/LEF family that act as heterodimeric transcription partners. TCFs act with corepressors including the TLE family (Groucho homologs). Additional regulators include CREBBP (CBP), PYGO1 (Pygopos) and CTNNBIP1 (ICAT). TCF7, the major TCF/LEF expressed in NBs, was markedly more abundant in HR-NA NBs. There was also higher expression of CTNNBIP1 in these tumors, and lower expression of PYGO1.
Discussion
Embryonal malignancies frequently misappropriate developmental programs to drive neoplasia (Maris and Denny, 2002) . We hypothesized that activation of Wnt/ b-catenin might contribute to NB progression as pathway mutations occur in other pediatric embryonal cancers and tumors of neural crest lineage (reviewed in Giles et al. (2003) ). b-catenin also plays a key role in premigratory neural crest development Kleber et al., 2005) , maintenance and expansion of neural crest stem cells (Chenn and Walsh, 2002; Reya and Clevers, 2005) and proliferative control of neural progenitors (Zechner et al., 2003) . Similar functions may contribute to oncogenesis in neural precursors. Nearly half of all children with NB present with clinicobiological factors that define their tumors as highrisk. MYCN amplification occurs in B40% yet no consistent pathway alteration accounts for the highly aggressive phenotype in the remainder. We speculated that deregulated MYC and additional b-catenin targets might be implicated. Interestingly, MYC (rather than MYCN) acts as an essential regulator of earlier neural crest formation in vertebrates, and its expression is dependent upon Wnt/b-catenin signaling (Bellmeyer et al., 2003) .
We demonstrate that b-catenin is highly expressed and aberrantly localized in NB cells absent MYCN amplification. The nuclear distribution of b-catenin is homogeneous in comparison to HepG2 cells and may reflect different alterations in b-catenin regulation in NBs than those Figure 4 Box-plots for all differentially expressed b-catenin targets across NB subsets. As labeled across bottom, the left-most box represents expression values from 28 intermediate-risk NBs (IR), the center box 32 HR-NA NBs and the right-most box the 20 HR-A NBs. Each box represents the 25th through 75th percentile with the median marked by a dot; caps span to the 10th and 90th percentile. Statistically significant expression differences (by PaGE analyses) are denoted by the asterisk (*) using a false-discovery rate of 0.1.
Deregulated b-catenin in neuroblastoma X Liu et al resulting from activating mutations in b-catenin. Indeed, we failed to identify any b-catenin-specific mutations in NB. Our cell line findings suggest canonical b-catenin signaling activity, yet we were unable to directly demonstrate b-catenin transactivation. b-catenin may function through interactions with non-TCFLEF heterodimeric partners such as those of the SOX or FOXO families (Sinner et al., 2004; Essers et al., 2005) . Further, it is possible that relative upregulation of b-catenin target genes may be achieved through derepression of TCF complexes at b-catenin target genes in the absence of overt transactivation.
High-risk NBs without MYCN amplification showed more abundant WNT ligand expression consistent with autocrine or paracrine signaling, as has been described for breast and ovarian carcinomas (Bafico et al., 2004) . WNT5A has been reported to be reduced in NBs with high-risk features (Blanc et al., 2005) , but our datasets demonstrate low expression in both high (Table 3) and lower-risk tumors with no differential expression (data not shown). Still, most tumor-specific pathway deregulation occurs through activating mutations downstream of Wnt/receptor events. DVL1 is one intermediate demonstrating elevated expression in NBs without MYCN amplification, a direction consistent with activation. Extensive studies have not been done to exclude activating mutations in other components of the b-catenin scaffold and degradation complex to date, though our data suggest such studies are warranted. Finally, evidence in support of aberrant b-catenin signaling in high-risk NBs without MYCN amplification comes from expression profile analyses of b-catenin target genes.
We queried colorectal cancer registries for NBs occurring in familial adenomatous polyposis (FAP) kindreds, but did not identify any (F Giardiello, personal communication). b-catenin has instructive influences on neural crest stem cells driving sensory neuron expansion at the expense of autonomic neurons , including the sympathetic ganglia at risk of neuroblastic transformation. It is possible that germ line activation of b-catenin through mutant APC leads to temporal pathway activation that precludes NB. Hepatoblastomas demonstrate b-catenin pathway mutations in two-thirds of sporadic cases, yet fewer than 1% of patients with germ line APC mutations (FAP) are diagnosed with this embryonal tumor (Taipale and Beachy, 2001 ).
In conclusion, we have defined the b-catenin pathway as potentially contributing to highly aggressive NB in the absence of MYCN amplification. The specific mechanisms whereby the b-catenin pathway is activated in NB remain elusive and it is possible that activation in additional cellular pathways may contribute, but classical tumor-specific mutations in scaffolding and regulatory proteins have not been wholly excluded. That the pathway may contribute to NB tumorigenesis is of clinical relevance as therapies targeting this pathway are under development (Moon et al., 2004) . The relative importance in NB remains to be elucidated and functional evidence supporting a cellular dependence on this pathway has not been demonstrated. Still, the data herein support that preclinical evaluation of b-catenin-targeted therapies may be warranted. . A nonrandom distribution of target genes is apparent, with upregulation in the HR-NA tumors. This is statistically confirmed with an enrichment score (ES) that reflects the degree to which this gene set is overrepresented at the extremes in the analysis (P ¼ 0.04). The 'leading edge' subset of genes is circled and defines the core members that participate in defining the phenotype (b-catenin targets upregulated in the HR-NA NBs and listed in the text).
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Materials and methods

Cell lines and primary tumors
The NB cell lines used are referenced in Thompson et al. (2001) and propagated as described. HepG2, NALM-6 (pre-B ALL) and PB1 (T-cell lymphoma) cells were kindly provided by Dr Mariusz Ratajczak (University of Pennsylvania). Twenty-six tumoral DNA samples were obtained from the former Children's Cancer Group tumor bank for b-catenin mutation analyses. For oligonucleotide array-based expression profile studies, 73 primary NBs were used (Wang et al., 2006) as detailed below.
RNA isolation and qRT-PCR analysis RNA was isolated using RNeasy (Qiagen, Valencia, CA, USA). Reverse transcription (RT)-PCR was used for evaluation of MYC, MYCN, CCND1 and NRCAM. RNA (2 mg) was reverse transcribed using the SuperScript II pre-amplification system (Life Technologies, Gaithersburg, MD, USA). One microliter of product was used as a template for PCR amplification using biotinylated glyceraldehyde-3-phosphate dehydrogenase (GAPDH) primers multiplexed with target gene primers (all primer pairs spanned an intron-exon boundary; sequences available upon request). GAPDH primers were used at a ratio of biotinylated:non-biotinylated of 1:99 to prevent signal saturation (Eggert et al., 2000) . PCR was performed in 20 ml volumes containing 400 nM each primer, 0.1 mM each deoxyribonucleotide triphosphate, 1.5 mM MgCl 2 , 1 Â PCR buffer and one unit of AmpliTaq Gold polymerase (PerkinElmer Corp, Branchburg, NJ, USA) for 18 (MYC, MYCN) or 30 cycles (CCND1, NRCAM) at an annealing temperature of 55 1C. Detection was performed using the Southern Light system (Tropix Inc., Bedford, MA, USA).
Protein fractionation and immunoblotting
Fractionated nuclear and cytosolic protein lysates were obtained using the NE-PER Extraction Reagents kit (Pierce; Rockford, IL, USA). Fresh MiniComplete protease inhibitor cocktail (Roche) was added. Ten micrograms of nuclear protein or 50 mg of cytosolic protein was loaded. Antibodies included anti-b-catenin (C19220; BD Transduction Laboratories, San Jose, CA, USA), anti-N-myc (556438, BD PharMingen, San Jose, CA, USA), anti-Myc (C33, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and anti-btubulin (D-10, Santa Cruz Biotechnology). Detection was via goat anti-mouse secondary antibody with chemiluminescence detection (Immun-Star; Bio Rad Laboratories, Hercules, CA, USA). Ponceau S staining was used to ensure balanced loading for subcellular fractions but no normalization of target to control signals was used. Semiquantitation was performed using densitometric detection (NIH Image, v1.5 software).
Immunofluorescence Cells were subconfluently seeded in Nunc Lab-Tek II chamber slides (Fisher Scientific, Pittsburgh, PA, USA) before fixation with ice-cold 1:1 methanol:acetone solution for 10 min. Cells were washed in phosphate-buffered saline (PBS) and stored at À20 1C after air-drying. Slides were blocked with 50 ml of PBS þ 1% bovine serum albumin for 10 min, then incubated with 40 ml of a b-catenin-fluorescein isothyocyanate antibody (C19224, Transduction Laboratories) at 10 mg ml À1 for 45 min at room temperature (RT). After washing in PBS (thrice Â 5 min), cells were counterstained with 4'-6-diamidino-2-phenylindole (DAPI; 450 ng ml À1 ) in PBS for 15 min, washed in deionized water thrice for 15 min before mounting with antifade reagent (SlowFade; Molecular Probes, Inc., Eugene, OR, USA) and viewed with a Leica DMR Fluorescence Microscope.
b-Catenin mutation analysis For PCR-based SSCP, DNA was amplified as previously reported (Voeller et al., 1998) with 100 mM dATP including half Redivue [a-32 P] dATP (Amersham Pharmacia, Buckinghamshire, UK). Denatured samples were electrophoresed through a 6% non-denaturing mutation detection enhancement gel (Cambrex) at both 4 1C and (25 1C). Internal deletions were also screened for with primers within exons 2 (5 0 -ATTGGG GCTCTGCTTCGTTG-3 0 ) and 4 (5 0 -GTCATTGCTTACC TGGTCCTCG-3 0 ).
b-Catenin/TCF reporter assays Cells were transiently transfected with pTOPflash or pFOPflash (Morin et al., 1997) provided by Dr Bert Vogelstein (The Johns Hopkins University) as described previously (Kolligs et al., 2002) . HEK 293 cells transfected to express S33Y mutant b-catenin were used as a positive control. Each experiment was performed twice in triplicate, and mean and s.d. values were determined.
Oligonucleotide-array profiling Expression profiles from diagnostic NBs (Wang et al., 2006) using the Affymetrix U95Av2 array (Affymetrix, Santa Clara, CA, USA) were mined. Modeling of probe set behavior was conducted using Probe Profiler (Corimbia, Berkeley, CA, USA) software that implements a model-based approach and corrects for nonspecific cross-hybridization effects. A quantitative expression score (e-score) is calculated for each probe set (see the GEO database at http://www.ncbi.nlm.nih.gov/geo/ (accession number GSE3960)). b-Catenin pathway component genes were hand curated (see Table 3 ); the b-catenin target gene set was defined a priori using the Wnt/b-catenin database (www.stanford.edu/Brnusse/wntwindow.html). Probe sets for twenty-six genes were included: CCND1, MYC, PPARD, NRCAM, TCF7, LEF1, FOSL1, JUN, MMP7, TCF4, VEGF, (Manduchi et al., 2000) ) algorithm. All runs were done with 1000 permutations on unlogged data. A confidence level of 0.95 (1-FDR) was used to define differential expression.
Unsupervised clustering
Expression values were filtered from the HGU95Av2 data sets for 21 intermediate-risk NBs (IR), 32 high-risk NBs without MYCN amplification (HR-NA) and 20 high-risk NBs with MYCN amplification (HR-A). Unsupervised agglomerative hierarchical clustering was performed on TIGR's MultiExperiment Viewer. Manhattan distance was used as the distance metric and average linkage, which is the average distance between each component of one cluster and each component of the other cluster was used to measure cluster-tocluster distances.
Gene set enrichment analysis GSEA was used to compare profiles across biological classes (Subramanian et al., 2005) . Expression values from samples were stratified by NB risk group in binary comparisons, and ranked based on the correlation between their expression and the biological class distinction. The GSEA-P software package was used (Broad Institute, Massachusetts Institute of Technology) with the 26 b-catenin target genes as our 'gene set', and an ES that reflects the degree to which a gene set is overrepresented at the extremes of the gene rank list in a two-group comparison and corresponds to a weighted statisic like Kolmogorov-Smironov was calculated. Statistical significance is estimated by generation of a nominal P-value following random permutation of the Group labels to compute a series of ESs and define the null distribution for this metric (Subramanian et al., 2005) .
